Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 10/20 | 0.40 |
| ▸ | PLAU | P00749 | 10/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323287 | 1.00 | NR3C1 (0.52) | NR3C1FABP4FABP3FABP5GAA | |
| SCHEMBL21922801 | 0.77 | FABP4 (0.62) | NR3C1FABP4FABP3FABP5GAA | |
| SCHEMBL10452159 | 0.75 | FABP4 (0.60) | NR3C1FABP4FABP3FABP5GAA | |
| SCHEMBL17115758 | 0.74 | FABP4 (0.50) | NR3C1FABP4FABP3FABP5GAA | |
| SCHEMBL6323293 | 0.74 | FABP4 (0.50) | NR3C1FABP4FABP3FABP5GAA | |
| SCHEMBL675038 | 0.74 | FABP4 (0.58) | NR3C1FABP4FABP3FABP5GAA | |
| SCHEMBL1767682 | 0.74 | FABP4 (0.63) | NR3C1FABP4FABP3FABP5GAA | |
| SCHEMBL4119631 | 0.73 | NR3C1 (0.58) | NR3C1 | |
| SCHEMBL6326224 | 0.73 | NR3C1 (0.51) | NR3C1GAAALDH1A1 | |
| SCHEMBL6330641 | 0.73 | NR3C1 (0.58) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | NR3C1 4639/4885FABP4 2333/4885FABP3 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.